[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100517064":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":30,"studyPopulation":30,"armGroups":42,"interventions":58,"overallOfficials":30,"centralContacts":67,"locations":30,"responsibleParty":77,"collaborators":79,"id":83,"slug":30,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":30,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":30,"overallStatus":103,"whyStopped":30,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":30},{"fullName":5,"class":6},"Medical University of Bialystok","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":30},[9],{"measure":10,"description":11,"timeFrame":12},"Effects of metformin on fertility and the possibility of becoming pregnant,as measured by pregnancy test strips and β-hCG levels","The aim of the study is to evaluate the effect of metformin on endometrial function in women diagnosed with idiopathic infertility, by proving the use of the proposed therapy to improve fertility in these women.","4 years",[14,17,20,23,26],{"measure":15,"description":16,"timeFrame":12},"Evaluation of the effect of metformin therapy on endometrial function.","It will be tested by assessing the concentration of biomarkers in the tissue before and after treatment",{"measure":18,"description":19,"timeFrame":12},"Molecular analysis of endometrial tissues using Next Generation Sequencing (NGS) technology","Transcriptome analysis of endometrial tissues before and after metformin therapy.",{"measure":21,"description":22,"timeFrame":12},"Intra-tissue metabolic profiling of steroids","The study will test whether treatment with metformin affects the intracrine production of steroid hormones in the endometrium.",{"measure":24,"description":25,"timeFrame":12},"Oxidative stress evaluation by using total oxidative capacity (TOC) and total antioxidant capacity (TAC)","In-depth analysis of molecular and cellular processes using multi-omics combined with clinical data will provide essential knowledge about the mechanisms of metformin's action, which may have clinical applications not only in cases of idiopathic female infertility but also in other disorders.",{"measure":27,"description":28,"timeFrame":29},"Quality of Life questionary evaluation SF-36, FertiQoL,","The results on the response scales are rotatable, summed and scaled from 0 to 100. Subscale and higher scores indicate good quality life. The number of obtained equation points is 50 or less arrangements with a psychologist.","24 weeks",null,{"allocation":32,"interventionModel":33,"interventionModelDescription":30,"primaryPurpose":34,"observationalModel":30,"timePerspective":30,"maskingInfo":35},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":36,"maskingDescription":30,"whoMasked":37},"QUADRUPLE",[38,39,40,41],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[43,49,55],{"label":44,"type":45,"description":46,"interventionNames":47},"metformin","EXPERIMENTAL","patients randomized to received metformin",[48],"Drug: Metformin Hydrochloride",{"label":50,"type":51,"description":52,"interventionNames":53},"placebo","PLACEBO_COMPARATOR","patients randomized to received placebo",[54],"Drug: Placebo",{"label":56,"type":57,"description":30,"interventionNames":30},"group without intervention","NO_INTERVENTION",[59,64],{"type":60,"name":61,"description":62,"armGroupLabels":63,"otherNames":30},"DRUG","Metformin Hydrochloride","The investigational medicinal product\u002Fplacebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.\n\nThe randomized patient will receive the investigational medicinal product\u002Fplacebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product\u002Fplacebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg\u002Fday to 1500 mg\u002Fday in order to avoid or reduce side effects related to taking the study medicinal product metformin",[44],{"type":60,"name":65,"description":62,"armGroupLabels":66,"otherNames":30},"Placebo",[50],[68,73],{"name":69,"role":70,"phone":71,"phoneExt":30,"email":72},"Monika Zbucka-Krętowska, Associate Professor","CONTACT","+48 85 831 87 89","monika.zbucka-kretowska@umb.edu.pl",{"name":74,"role":70,"phone":75,"phoneExt":30,"email":76},"Clinical Research Support Center","+48 85 686 53 86","owbk@umb.edu.pl",{"type":78,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR",[80],{"name":81,"class":82},"Medical Research Agency, Poland","OTHER_GOV","100517064",false,"NCT06012682","Clinical Trials Evaluating the Effect of Metformin Treatment on Function Endometrium in Women Diagnosed With Idiopathic Infertility","A Randomized, Controlled, Double-blind Study Clinical Trials Evaluating the Effect of Metformin Treatment on Function Endometrium in Women Diagnosed With Idiopathic Infertility","METIN","Inclusion Criteria:\n\n1. Age 18-45\n2. No pregnancy for a minimum of 12 months prior to screening.\n3. Diagnosed with idiopathic infertility.\n4. No use of hormone therapy 30 days before screening.\n5. No use of any methods of contraception 30 days before screening and during the examination.\n6. BMI between 18.5 - 30 kg\u002Fm2.\n\nExclusion Criteria:\n\n1. Positive pregnancy test result.\n2. Patients diagnosed with another factor of infertility.\n3. Patients with type I or II diabetes.\n4. Patients taking metformin or other hypoglycaemic drugs in the last 4 weeks before screening.\n5. Patients with hepatic impairment and abnormal liver function tests (alanine aminotransferase and\u002For aspartate aminotransferase (above 3x ULN).\n6. Patients with an eGFR less than 45 mL\u002Fmin\u002F1.73m2.\n7. Accompanying chronic diseases with poor prognosis.\n8. Patients with a history of lactic acidosis or other metabolic acidosis.\n9. Patients with a history of congestive heart failure III\u002FIV NYHA degree.\n10. Patients with acute myocardial ischemia.\n11. Patients with sepsis or severe infection.\n12. Diseases which, in the opinion of the investigator, constitute an exclusion criterion and prevent the patient from participating in the study.\n13. Patients with predictable problems with cooperation with the research team.",true,"FEMALE","18 Years","45 Years",{"count":95,"type":96},200,"ESTIMATED","INTERVENTIONAL",[99],"PHASE2","Randomized, controlled, double-blind, three-arm clinical trial in which 75 women will be randomized to treatment with metformin, 75 women to treatment with placebo and 50 women to the observation group. The medical intervention will last 24 weeks (6 months). Women with confirmed idiopathic infertility, in whom infertility factors have been excluded during full diagnostics, will be included in the study",[102],"Infertility, Female","NOT_YET_RECRUITING","2023-08-22",{"date":106,"type":107},"2023-08-25","ACTUAL",{"date":109,"type":96},"2023-08-30",{"date":111,"type":96},"2027-09-30",{"name":5,"class":6}]